logo-loader

ImmuPharma extends exclusivity period for its collaboration talks with Incanthera

Published: 07:10 31 Dec 2018 GMT

Cogs of collaboration
The wheels are turning but it has not been possible to complete negotiations by the deadline

The exclusivity agreement between ImmuPharma PLC (LON:IMM) and Incanthera Limited, due to expire at midnight today, has been extended to the end of March.

ImmuPharma announced on 7 September a clinical development collaboration for its Nucant cancer programme with specialist oncology development company, Incanthera, but it has yet to finalise the definitive licence agreement'.

REA: ImmuPharma says managed access programme for Lupozor progressing as planned

It is now envisaged that the agreement will be finalised in the first quarter of 2019 and as such, a further update on this collaboration will be announced in due course.

"We are working diligently with Incanthera's management team to finalise the last remaining parts to the 'Definitive Licence Agreement' and look forward to updating the market and shareholders in Q1 2019,” said Dimitri Dimitriou, the chief executive officer of ImmuPharma.

ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug...

ImmuPharma PLC (AIM:IMM) chief executive Tim McCarthy provides an extensive update during an interview with Proactive's Stephen Gunnion, focusing on the financial, business, and portfolio developments of the company. McCarthy clarified that the company is in a strong financial position,...

3 weeks, 1 day ago